Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Oncology (Williston Park, N.Y.)|March 21, 2007
First-Cycle CSF use in breast cancer and NHL: guidelines and recommendationsAref Al-Kali, Howard Ozer
Journal of Blood Medicine|January 28, 2012
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)Aref Al-Kali, William Wierda, Michael Keating, et al.
International Journal of Molecular Sciences|June 12, 2026
Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional NetworksAli Tarhini, Michael Romanos, Aref Al-Kali, et al.
Future Oncology (London, England)|August 31, 2010
Forodesine: review of preclinical and clinical dataAref Al-Kali, Varsha Gandhi, Mohamad Ayoubi, et al.
The American Journal of the Medical Sciences|March 18, 2010
Papillary renal cell carcinoma with cutaneous metastasesNandakumar Srinivasan, Aneesh Pakala, Aref Al-Kali, et al.
Cancers|July 15, 2026
Clinical and Prognostic Significance of <i>CEBPA</i> Mutations in Myelodysplastic SyndromesMohamed M Khamis, Aref Al-Kali, Omar Alkharabsheh, et al.
Leukemia Research|February 5, 2020
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'Caleb J Scheckel, Megan Meyer, Jeffrey Alan Betcher, et al.
Blood Cancer Journal|January 4, 2023
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitorNaseema Gangat, Kebede H Begna, Aref Al-Kali, et al.
Hypoxia (Auckland, N.Z.)|December 20, 2019
An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23Daisheng Song, Wei Guan, Lea M Coon, et al.
American Journal of Ophthalmology Case Reports|May 5, 2022
Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven RetinopathyLauren A Dalvin, Timothy W Olsen, Sophie J Bakri, et al.
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Oncology (Williston Park, N.Y.)|March 21, 2007
First-Cycle CSF use in breast cancer and NHL: guidelines and recommendationsAref Al-Kali, Howard Ozer
Journal of Blood Medicine|January 28, 2012
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)Aref Al-Kali, William Wierda, Michael Keating, et al.
International Journal of Molecular Sciences|June 12, 2026
Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional NetworksAli Tarhini, Michael Romanos, Aref Al-Kali, et al.
Future Oncology (London, England)|August 31, 2010
Forodesine: review of preclinical and clinical dataAref Al-Kali, Varsha Gandhi, Mohamad Ayoubi, et al.
The American Journal of the Medical Sciences|March 18, 2010
Papillary renal cell carcinoma with cutaneous metastasesNandakumar Srinivasan, Aneesh Pakala, Aref Al-Kali, et al.
Cancers|July 15, 2026
Clinical and Prognostic Significance of <i>CEBPA</i> Mutations in Myelodysplastic SyndromesMohamed M Khamis, Aref Al-Kali, Omar Alkharabsheh, et al.
Leukemia Research|February 5, 2020
Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'Caleb J Scheckel, Megan Meyer, Jeffrey Alan Betcher, et al.
Blood Cancer Journal|January 4, 2023
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitorNaseema Gangat, Kebede H Begna, Aref Al-Kali, et al.
Hypoxia (Auckland, N.Z.)|December 20, 2019
An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23Daisheng Song, Wei Guan, Lea M Coon, et al.
American Journal of Ophthalmology Case Reports|May 5, 2022
Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven RetinopathyLauren A Dalvin, Timothy W Olsen, Sophie J Bakri, et al.
Pageof 15